Insmed Incorporated (0JAV.L)
USD 71.8
(-4.53%)
USD 71.8
(-4.53%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -654.73 Million USD | -47.08% |
| 2022 | -429.43 Million USD | -22.72% |
| 2021 | -375.09 Million USD | -43.7% |
| 2020 | -250.37 Million USD | -12.58% |
| 2019 | -215.67 Million USD | 24.45% |
| 2018 | -293.77 Million USD | -61.96% |
| 2017 | -184.09 Million USD | -8.85% |
| 2016 | -170.23 Million USD | -47.44% |
| 2015 | -115.28 Million USD | -34.74% |
| 2014 | -86.09 Million USD | -60.43% |
| 2013 | -54.2 Million USD | -29.83% |
| 2012 | -40.05 Million USD | -18.34% |
| 2011 | -59.31 Million USD | -340.23% |
| 2010 | -6.19 Million USD | -0.89% |
| 2009 | 120.31 Million USD | 38.09% |
| 2008 | -13.36 Million USD | 35.77% |
| 2007 | -18.87 Million USD | 54.37% |
| 2006 | -49.06 Million USD | -201.99% |
| 2005 | -13.78 Million USD | 46.93% |
| 2004 | -27.16 Million USD | -164.11% |
| 2003 | -10.49 Million USD | 36.09% |
| 2002 | -34.14 Million USD | 58.01% |
| 2001 | -38.64 Million USD | -292.05% |
| 2000 | -30.31 Million USD | 350.16% |
| 1999 | -8.04 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -182.5 Million USD | -107.98% |
| 2024 Q1 | -154.55 Million USD | 17.91% |
| 2024 Q3 | -213.42 Million USD | 28.73% |
| 2023 Q2 | -221.59 Million USD | -50.74% |
| 2023 Q4 | -158.62 Million USD | -15.95% |
| 2023 Q3 | -136.8 Million USD | 38.26% |
| 2023 FY | - USD | -47.08% |
| 2023 Q1 | -147 Million USD | 1.39% |
| 2022 Q1 | -89.35 Million USD | 11.06% |
| 2022 FY | - USD | -22.72% |
| 2022 Q4 | -149.08 Million USD | -17.3% |
| 2022 Q3 | -127.09 Million USD | -39.33% |
| 2022 Q2 | -91.22 Million USD | -2.09% |
| 2021 FY | - USD | -43.7% |
| 2021 Q3 | -101.13 Million USD | -18.24% |
| 2021 Q4 | -100.46 Million USD | 0.66% |
| 2021 Q2 | -85.53 Million USD | -6.15% |
| 2021 Q1 | -80.57 Million USD | 13.23% |
| 2020 Q3 | -53.03 Million USD | -4.0% |
| 2020 Q1 | -57.15 Million USD | -23.95% |
| 2020 Q4 | -92.86 Million USD | -75.1% |
| 2020 Q2 | -50.99 Million USD | 10.78% |
| 2020 FY | - USD | -12.58% |
| 2019 Q2 | -60.14 Million USD | 11.11% |
| 2019 Q4 | -46.11 Million USD | 15.66% |
| 2019 FY | - USD | 24.45% |
| 2019 Q3 | -54.66 Million USD | 9.1% |
| 2019 Q1 | -67.66 Million USD | 21.71% |
| 2018 Q2 | -71.7 Million USD | -15.2% |
| 2018 Q1 | -62.24 Million USD | 4.62% |
| 2018 FY | - USD | -61.96% |
| 2018 Q4 | -86.42 Million USD | -3.84% |
| 2018 Q3 | -83.22 Million USD | -16.06% |
| 2017 FY | - USD | -8.85% |
| 2017 Q1 | -35.34 Million USD | 47.26% |
| 2017 Q4 | -65.25 Million USD | -50.83% |
| 2017 Q2 | -42.57 Million USD | -20.45% |
| 2017 Q3 | -43.26 Million USD | -1.62% |
| 2016 Q4 | -67.02 Million USD | -83.98% |
| 2016 Q3 | -36.43 Million USD | -2.52% |
| 2016 FY | - USD | -47.44% |
| 2016 Q1 | -33.05 Million USD | -1.43% |
| 2016 Q2 | -35.53 Million USD | -7.51% |
| 2015 Q3 | -29.84 Million USD | -8.5% |
| 2015 Q1 | -26.23 Million USD | -13.7% |
| 2015 Q4 | -32.58 Million USD | -9.17% |
| 2015 FY | - USD | -34.74% |
| 2015 Q2 | -27.51 Million USD | -4.85% |
| 2014 Q2 | -22.64 Million USD | -26.27% |
| 2014 Q4 | -23.07 Million USD | -0.1% |
| 2014 FY | - USD | -60.43% |
| 2014 Q1 | -17.93 Million USD | -16.27% |
| 2014 Q3 | -23.05 Million USD | -1.82% |
| 2013 Q1 | -14.16 Million USD | 9.74% |
| 2013 FY | - USD | -29.83% |
| 2013 Q4 | -15.42 Million USD | 7.49% |
| 2013 Q3 | -16.67 Million USD | -105.49% |
| 2013 Q2 | -8.11 Million USD | 42.71% |
| 2012 Q2 | -9.84 Million USD | -38.12% |
| 2012 Q1 | -7.12 Million USD | 18.63% |
| 2012 FY | - USD | -18.34% |
| 2012 Q4 | -15.68 Million USD | -70.26% |
| 2012 Q3 | -9.21 Million USD | 6.4% |
| 2011 FY | - USD | -340.23% |
| 2011 Q2 | -10.39 Million USD | -41.61% |
| 2011 Q1 | -7.34 Million USD | -16.49% |
| 2011 Q3 | -8.97 Million USD | 13.7% |
| 2011 Q4 | -8.76 Million USD | 2.34% |
| 2010 Q1 | -226 Thousand USD | -158.1% |
| 2010 Q4 | -6.3 Million USD | -953.68% |
| 2010 FY | - USD | -0.89% |
| 2010 Q2 | -913 Thousand USD | -303.98% |
| 2010 Q3 | -598 Thousand USD | 34.5% |
| 2009 Q4 | 389 Thousand USD | 150.92% |
| 2009 FY | - USD | 38.09% |
| 2009 Q2 | -798 Thousand USD | 88.12% |
| 2009 Q1 | -6.71 Million USD | -91.53% |
| 2009 Q3 | -764 Thousand USD | 4.26% |
| 2008 Q4 | -3.5 Million USD | -121.88% |
| 2008 Q2 | -4.11 Million USD | 0.07% |
| 2008 Q3 | -1.58 Million USD | 61.54% |
| 2008 Q1 | -4.11 Million USD | -28.68% |
| 2008 FY | - USD | 35.77% |
| 2007 Q4 | -3.19 Million USD | 20.71% |
| 2007 Q3 | -4.03 Million USD | -62.38% |
| 2007 Q2 | -2.48 Million USD | 75.94% |
| 2007 Q1 | -10.32 Million USD | 50.69% |
| 2007 FY | - USD | 54.37% |
| 2006 Q3 | -12.63 Million USD | -36.74% |
| 2006 Q2 | -9.24 Million USD | -12.78% |
| 2006 Q1 | -8.19 Million USD | -481.96% |
| 2006 Q4 | -20.93 Million USD | -65.65% |
| 2006 FY | - USD | -201.99% |
| 2005 Q1 | -5.29 Million USD | 9.91% |
| 2005 Q2 | -5.6 Million USD | -5.8% |
| 2005 FY | - USD | 46.93% |
| 2005 Q3 | -2.22 Million USD | 60.24% |
| 2005 Q4 | -1.4 Million USD | 36.8% |
| 2004 Q2 | -9.05 Million USD | -87.72% |
| 2004 Q1 | -4.82 Million USD | -93.69% |
| 2004 FY | - USD | -164.11% |
| 2004 Q3 | -7.64 Million USD | 15.58% |
| 2004 Q4 | -5.88 Million USD | 23.04% |
| 2003 Q1 | -2.27 Million USD | 29.41% |
| 2003 FY | - USD | 36.09% |
| 2003 Q4 | -2.48 Million USD | -1.8% |
| 2003 Q3 | -2.44 Million USD | 25.57% |
| 2003 Q2 | -3.28 Million USD | -44.65% |
| 2002 Q1 | -6.19 Million USD | 36.66% |
| 2002 Q2 | -7.16 Million USD | -15.73% |
| 2002 FY | - USD | 58.01% |
| 2002 Q4 | -18.6 Million USD | -1029.77% |
| 2002 Q3 | -2.18 Million USD | 104.83% |
| 2001 FY | - USD | -292.05% |
| 2001 Q4 | -9.77 Million USD | -13.5% |
| 2001 Q3 | -8.61 Million USD | 7.08% |
| 2001 Q2 | -9.26 Million USD | 15.66% |
| 2001 Q1 | -10.98 Million USD | -126.28% |
| 2000 FY | - USD | 350.16% |
| 2000 Q4 | 41.82 Million USD | 900.23% |
| 2000 Q3 | -5.22 Million USD | 90.58% |
| 2000 Q1 | -11.39 Million USD | 0.0% |
| 2000 Q2 | -55.5 Million USD | -386.99% |
| 1999 Q1 | -1.56 Million USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q2 | -1.65 Million USD | -6.15% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | -301.392% |
| Dynavax Technologies Corporation | 9.66 Million USD | 6873.629% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 766.32% |
| Perrigo Company plc | 646.2 Million USD | 201.321% |
| Illumina, Inc. | -608 Million USD | -7.687% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 106.062% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | -45.817% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 94.195% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 120.109% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -530.818% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 114.068% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -1656.133% |
| Waters Corporation | 1.02 Billion USD | 164.049% |
| Biogen Inc. | 2.37 Billion USD | 127.545% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -648.898% |
| Evolus, Inc. | -41.81 Million USD | -1465.987% |
| Adicet Bio, Inc. | -136.53 Million USD | -379.539% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -456.514% |
| bluebird bio, Inc. | -167.16 Million USD | -291.682% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -336.179% |
| FibroGen, Inc. | -261.4 Million USD | -150.469% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 139.042% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -1373.419% |
| Homology Medicines, Inc. | -47.75 Million USD | -1271.009% |
| Geron Corporation | -174.78 Million USD | -274.603% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | -187.014% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -611.062% |
| Myriad Genetics, Inc. | -67.8 Million USD | -865.692% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -549.369% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | -29.315% |
| Zoetis Inc. | 3.68 Billion USD | 117.768% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -1194.667% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 156.247% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 311.013% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 114.217% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -1714.586% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | -184.657% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | -146.145% |
| Verastem, Inc. | -83.16 Million USD | -687.268% |
| Nektar Therapeutics | -243.1 Million USD | -169.321% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -191.007% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -644.148% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | -49.077% |
| OPKO Health, Inc. | -65.51 Million USD | -899.357% |
| Exelixis, Inc. | 196.6 Million USD | 433.028% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 257.351% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 704.427% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -1074.293% |
| uniQure N.V. | -253.1 Million USD | -158.688% |
| Imunon, Inc. | -20.78 Million USD | -3050.468% |
| Blueprint Medicines Corporation | -474.61 Million USD | -37.952% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 244.871% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | -89.524% |
| TG Therapeutics, Inc. | 26.1 Million USD | 2608.579% |
| Incyte Corporation | 919.42 Million USD | 171.212% |
| Emergent BioSolutions Inc. | -505.29 Million USD | -29.574% |